For Richard and Michelle Schlueter, the National Institutes of Health is more than a world-renowned research hospital. It is, as patients lovingly call it, the National Institutes of Hope. When Richard arrived there with stage 4 head and neck cancer, having been told his disease would end his life, the couple was embraced not just by cutting-edge science but by profound human kindness. They recall scientists who could earn far more elsewhere but are driven by mission, and staff whose empathy shone in small gestures, from finding a favorite snack to watching a baseball game with a homesick patient from Georgia. This environment, where relentless dedication meets deep compassion, gave Richard something precious after a dire diagnosis: a genuine glimmer of hope.
That hope was crystallized in an experimental immunotherapy treatment pioneered by Dr. Steven A. Rosenberg. The plan involved harvesting Richard's own tumor-fighting cells, known as TILs, and reinfusing them to attack his cancer. In early 2025, the cells were confirmed as viable. Then, progress stalled. Due to federal budget-related personnel cuts, two technicians crucial to preparing his treatment were let go. What should have been a three-week wait stretched into months, a devastating delay during which Richard's cancer progressed and his health deteriorated. His story became a stark, personal illustration of how policy decisions in Washington directly alter the trajectory of a patient's life, a reality that compelled the Schlueters to share their experience widely.
They carried that message to Capitol Hill in September, joining over 430 advocates from 40 states for the Rally for Medical Research. Their mission was to champion robust, sustained funding for the NIH, a cause that unites hundreds of medical research organizations. In meetings with legislators, Richard detailed how funding instability had jeopardized his care. He was far from alone in feeling the urgency. First-time attendees, from cancer researchers to nurses, spoke of a powerful obligation to advocate, with one longtime policy observer questioning what it says about a nation that would shrink investment in biomedical research. This public sentiment is strongly reflected in polling, which shows overwhelming voter support for increasing medical research funding, a priority that has found a bipartisan echo in Congress.
Indeed, both the Senate and House have rejected proposals for deep cuts to the NIH, instead proposing budget increases for the coming year. This longstanding congressional support was a focal point of gratitude for Rally participants. For the Schlueters, it allowed a heartfelt thank you to Senator Raphael Warnock, whose bipartisan advocacy helped reinstate a lab technician and ultimately enabled Richard to receive his long-delayed TIL infusion in August. While early scan results have been mixed, showing some tumors shrinking and others growing, the pioneering nature of the treatment allows for hope that a response may still develop. Richard's focus, however, extends beyond his own recovery. He sees the brilliant minds at the NIH unlocking cancer's secrets, and he understands that continued funding for this basic science is the essential foundation for the next generation of breakthroughs, a future the Rally fights to secure.